Zoetis Inc (ZTS) - Net Assets
Based on the latest financial reports, Zoetis Inc (ZTS) has net assets worth $5.40 Billion USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.16 Billion) and total liabilities ($9.76 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Zoetis Inc tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.40 Billion |
| % of Total Assets | 35.61% |
| Annual Growth Rate | 2.57% |
| 5-Year Change | 26.42% |
| 10-Year Change | 337.21% |
| Growth Volatility | 28.81 |
Zoetis Inc - Net Assets Trend (2010–2024)
This chart illustrates how Zoetis Inc's net assets have evolved over time, based on quarterly financial data. See Zoetis Inc (ZTS) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Zoetis Inc (2010–2024)
The table below shows the annual net assets of Zoetis Inc from 2010 to 2024. For live valuation and market cap data, see how much is Zoetis Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $4.77 Billion | -4.43% |
| 2023-12-31 | $4.99 Billion | +13.35% |
| 2022-12-31 | $4.40 Billion | -3.10% |
| 2021-12-31 | $4.54 Billion | +20.43% |
| 2020-12-31 | $3.77 Billion | +39.33% |
| 2019-12-31 | $2.71 Billion | +23.94% |
| 2018-12-31 | $2.19 Billion | +22.34% |
| 2017-12-31 | $1.79 Billion | +19.15% |
| 2016-12-31 | $1.50 Billion | +37.40% |
| 2015-12-31 | $1.09 Billion | -18.40% |
| 2014-12-31 | $1.34 Billion | +38.98% |
| 2013-12-31 | $962.00 Million | -76.19% |
| 2012-12-31 | $4.04 Billion | +8.16% |
| 2011-12-31 | $3.74 Billion | +11.72% |
| 2010-12-31 | $3.34 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zoetis Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1196800000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $11.97 Billion | 250.90% |
| Common Stock | $5.00 Million | 0.10% |
| Other Comprehensive Income | $-940.00 Million | -19.71% |
| Total Equity | $4.77 Billion | 100.00% |
Zoetis Inc Competitors by Market Cap
The table below lists competitors of Zoetis Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Swiss Re AG
SW:SREN
|
$34.98 Billion |
|
OTP Bank Nyrt
BUD:OTP
|
$34.99 Billion |
|
Axon Enterprise Inc.
NASDAQ:AXON
|
$35.09 Billion |
|
UNIV.MUSIC GRP.ADR/050
F:0VD0
|
$35.12 Billion |
|
Waters Corporation
NYSE:WAT
|
$34.91 Billion |
|
Hanwha Aerospace Co Ltd
KO:012450
|
$34.87 Billion |
|
Naspers Limited
JSE:NPN
|
$34.86 Billion |
|
Credo Technology Group Holding Ltd
NASDAQ:CRDO
|
$34.77 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zoetis Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,997,000,000 to 4,770,000,000, a change of -227,000,000 (-4.5%).
- Net income of 2,486,000,000 contributed positively to equity growth.
- Dividend payments of 786,000,000 reduced retained earnings.
- Share repurchases of 1,858,000,000 reduced equity.
- Other comprehensive income decreased equity by 101,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $2.49 Billion | +52.12% |
| Dividends Paid | $786.00 Million | -16.48% |
| Share Repurchases | $1.86 Billion | -38.95% |
| Other Comprehensive Income | $-101.00 Million | -2.12% |
| Other Changes | $32.00 Million | +0.67% |
| Total Change | $- | -4.54% |
Book Value vs Market Value Analysis
This analysis compares Zoetis Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.56x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 11.43x to 7.56x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $6.94 | $79.33 | x |
| 2011-12-31 | $7.72 | $79.33 | x |
| 2012-12-31 | $8.05 | $79.33 | x |
| 2013-12-31 | $1.88 | $79.33 | x |
| 2014-12-31 | $2.61 | $79.33 | x |
| 2015-12-31 | $2.13 | $79.33 | x |
| 2016-12-31 | $2.98 | $79.33 | x |
| 2017-12-31 | $3.59 | $79.33 | x |
| 2018-12-31 | $4.49 | $79.33 | x |
| 2019-12-31 | $5.62 | $79.33 | x |
| 2020-12-31 | $7.88 | $79.33 | x |
| 2021-12-31 | $9.53 | $79.33 | x |
| 2022-12-31 | $9.36 | $79.33 | x |
| 2023-12-31 | $10.81 | $79.33 | x |
| 2024-12-31 | $10.49 | $79.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zoetis Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 52.12%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 26.86%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 2.98x
- Recent ROE (52.12%) is above the historical average (40.71%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 3.29% | 3.07% | 0.68x | 1.58x | $-224.40 Million |
| 2011 | 6.59% | 5.79% | 0.74x | 1.54x | $-127.00 Million |
| 2012 | 10.83% | 10.06% | 0.69x | 1.56x | $33.40 Million |
| 2013 | 53.62% | 11.05% | 0.70x | 6.98x | $410.00 Million |
| 2014 | 44.47% | 12.18% | 0.73x | 5.03x | $451.90 Million |
| 2015 | 31.74% | 7.11% | 0.60x | 7.41x | $232.20 Million |
| 2016 | 55.21% | 16.80% | 0.64x | 5.14x | $672.30 Million |
| 2017 | 48.81% | 16.28% | 0.62x | 4.85x | $687.00 Million |
| 2018 | 65.35% | 24.52% | 0.54x | 4.93x | $1.21 Billion |
| 2019 | 55.39% | 23.96% | 0.54x | 4.26x | $1.23 Billion |
| 2020 | 43.46% | 24.54% | 0.49x | 3.61x | $1.26 Billion |
| 2021 | 44.84% | 26.20% | 0.56x | 3.06x | $1.58 Billion |
| 2022 | 47.99% | 26.16% | 0.54x | 3.39x | $1.67 Billion |
| 2023 | 46.91% | 27.43% | 0.60x | 2.86x | $1.84 Billion |
| 2024 | 52.12% | 26.86% | 0.65x | 2.98x | $2.01 Billion |
Industry Comparison
This section compares Zoetis Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $234,733,134
- Average return on equity (ROE) among peers: -29.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zoetis Inc (ZTS) | $5.40 Billion | 3.29% | 1.81x | $34.96 Billion |
| Aurora Cannabis Inc (ACB) | $1.68 Million | -10.54% | 0.00x | $177.38 Million |
| Akanda Corp (AKAN) | $4.28 Million | -95.78% | 0.85x | $7.56 Million |
| Akebia Ther (AKBA) | $68.12 Million | -199.28% | 3.41x | $263.59 Million |
| Alkermes Plc (ALKS) | $1.04 Billion | -15.16% | 0.88x | $7.35 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $1.64 Billion |
| Amphastar P (AMPH) | $448.72 Million | 0.31% | 0.41x | $854.96 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-186.87 Million | 0.00% | 0.00x | $5.18 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-186.87 Million | 0.00% | 0.00x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $263.49 Million | 12.07% | 0.07x | $190.27 Million |
| ANI Pharmaceuticals Inc (ANIP) | $457.60 Million | 4.10% | 0.98x | $1.80 Billion |
About Zoetis Inc
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and… Read more